- Home
- BFRI vs SYRS Comparison
BFRI vs SYRS Comparison
Compare BFRI & SYRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRI
- SYRS
- Stock Information
- Founded
- BFRI 1997
- SYRS 2011
- Country
- BFRI United States
- SYRS United States
- Employees
- BFRI N/A
- SYRS N/A
- Industry
- BFRI Biotechnology: Pharmaceutical Preparations
- SYRS Biotechnology: Pharmaceutical Preparations
- Sector
- BFRI Health Care
- SYRS Health Care
- Exchange
- BFRI Nasdaq
- SYRS Nasdaq
- Market Cap
- BFRI 6.2M
- SYRS 5.7M
- IPO Year
- BFRI 2021
- SYRS 2016
- Fundamental
- Price
- BFRI $1.11
- SYRS $0.17
- Analyst Decision
- BFRI Strong Buy
- SYRS Hold
- Analyst Count
- BFRI 1
- SYRS 5
- Target Price
- BFRI $7.00
- SYRS $3.00
- AVG Volume (30 Days)
- BFRI 158.3K
- SYRS 1.2M
- Earning Date
- BFRI 03-14-2025
- SYRS 03-26-2025
- Dividend Yield
- BFRI N/A
- SYRS N/A
- EPS Growth
- BFRI N/A
- SYRS N/A
- EPS
- BFRI N/A
- SYRS N/A
- Revenue
- BFRI $35,358,000.00
- SYRS $386,000.00
- Revenue This Year
- BFRI $17.69
- SYRS N/A
- Revenue Next Year
- BFRI $19.71
- SYRS N/A
- P/E Ratio
- BFRI N/A
- SYRS N/A
- Revenue Growth
- BFRI 5.17
- SYRS N/A
- 52 Week Low
- BFRI $0.65
- SYRS $0.16
- 52 Week High
- BFRI $2.43
- SYRS $7.96
- Technical
- Relative Strength Index (RSI)
- BFRI 49.87
- SYRS 38.78
- Support Level
- BFRI $1.06
- SYRS $0.16
- Resistance Level
- BFRI $1.16
- SYRS $0.20
- Average True Range (ATR)
- BFRI 0.07
- SYRS 0.02
- MACD
- BFRI -0.00
- SYRS 0.01
- Stochastic Oscillator
- BFRI 55.00
- SYRS 35.75
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.